TRA

Summary

TRA (T cell receptor alpha locus, HGNC:12027) is a protein-coding gene on chromosome 14q11.2, encoding M1-specific T cell receptor alpha chain (P0DSE1). The alpha chain of TRAV2701J4201C01/TRBV1901J2S701C02 alpha-beta T cell receptor (TR) clonotype that is specific for HLA-A*02:01-restricted M/matrix protein 1 immunodominant epitope GILGFVFTL of influenza A virus (IAV).

Enables signaling receptor activity. Contributes to peptide antigen binding activity. Involved in T cell activation involved in immune response; T cell mediated cytotoxicity directed against tumor cell target; and detection of tumor cell. Located in cell surface. Part of alpha-beta T cell receptor complex.

Source: NCBI Gene 6955 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 7 total
• Phenotypes (HPO): 1

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12027
Approved symbol	TRA
Name	T cell receptor alpha locus
Location	14q11.2
Locus type	gene with protein product
Status	Approved
Entrez	6955

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Human T cells potentially recognize through the alpha beta TCR HLA-E molecules that bind to class I- and virus-derived peptides. (PMID:11920559)
• variation of the alpha T cell repertoire in the colon of healthy individuals and patients with Crohn’s disease. (PMID:12039522)
• Self Ag recognition is mediated predominantly by TCR-alpha. (PMID:12444131)
• constitutive pre-TCR down-modulation regulates pre-TCR surface expression levels and hence the extent of ligand-independent signaling through the pre-TCR (PMID:12473666)
• T cell receptor itself is necessary and sufficient to confer HLA-independent nickel specificity. (PMID:12925207)
• Transgenic expression of the natural killer (NK) T cell-specific TCR alpha-chain Valpha14Jalpha18 leads to a complete restoration of NK T cell numbers in tyrosine kinase Fyn-deficient mice. (PMID:15128794)
• In TCR double-transgenic mice, peripheral T cells are functionally monospecific due to TCR alpha exclusion: one transgenic TCR alpha protein is selectively down-regulated from the thymocyte and T cell surface. (PMID:15494509)
• Hapten cross-reactivity happens w/o major adjustments to the interaction between the TCR & the HLA-A2 surface. TCRs have the molecular flexibility to accommodate structurally diverse ligands while conserving interactions with the MHC molecule surface. (PMID:16310048)
• Data are compatible with an instructive role for the TCR in alphabeta vs gammadelta lineage commitment, with gammadelta development as the default pathway for human thymocyte development. (PMID:16424183)
• FISH revealed breakpoints (BPs) in the T-cell receptor alpha/delta locus (14q11) and in the vicinity of the CCND2 gene at 12p13. (PMID:16548914)
• Endogenous and chimeric TCRs compete for cell-surface expression in favor of the TCR-CD3 complex with best-pairing properties. (PMID:16968899)
• different enzymatic activities operate during recombination of TCRA and TCRD genes, although they are located within the same genetic locus (PMID:17015149)
• analysis of TCRalpha-CD3deltaepsilon and TCRbeta-CD3gammaepsilon dimers and the role of the membrane-proximal tetracysteine motif (PMID:17023417)
• T cell receptor alpha-chain usage plays a critical role in controlling major histocompatiblity complex (MHC) restriction between closely related allomorphs. (PMID:17082594)
• T cell receptor V-J alpha recombination in the thymus is not random but depends on the reciprocal V alpha and J alpha position within the locus. (PMID:17391765)
• CD4positive CD25high regulatory T cells showing immunosuppressive functions use a large unrestricted alpha beta T cell receptor repertoire, the size and diversity of which are closely similar to those of CD4-positive CD25negative T cells. (PMID:17785774)
• An alanine scanning mutagenesis approach was undertook to define the energetic basis of this interaction between the natural killer cell T cell receptors and CD1d. (PMID:18378792)
• The alpha-chain connecting peptide motif of a T cell receptor (TCR) is an important element that mediates CD8 coreceptor approximation and signal initiation for positive thymic selection. (PMID:18523287)
• Decreased ER-associated degradation of TCRA induced by Grp78 depletion with the SubAB cytotoxin is reported. (PMID:18611445)
• Valpha7.2-Jalpha33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T cells (PMID:18927318)
• Stage-dependent molecular changes in Notch signaling that are critical for normal human T-cell development. (PMID:19056690)
• Association between narcolepsy and olymorphisms in the TRA@ (T-cell receptor alpha) locus, with genotypic odds ratio 1.94 and 2.55 in 1,830 cases, 2,164 controls. (PMID:19412176)
• TRAC variants associated with susceptibility to IgA nephropathy (PMID:19470682)
• Healthy survivors exhibit reductions in peripheral CD8 T cells, CD8 coreceptor, and TCR Valpha2 expression, triggered by multiple tolerance mechanisms in a spontaneous autoimmunity mouse model. (PMID:19675167)
• TCRalpha genes thus up for their lack of separate D segments with distinct D-like segments that are built into the 5’ ends of their J segments. (PMID:19756574)
• TCRA is a plausible candidate for susceptibility to essential hypersomnia patients positive for the HLA-DRB1*1501-DQB1*0602 haplotype. (PMID:19927159)
• Studies show that the analytic algorithm enables the comparison of alphabeta TCR repertoires between individuals and that abnormal alphabeta TCR repertoire is a feature of a subset of patients with advanced MDS. (PMID:20035823)
• Although the frequency of T cell receptor (TCR) alpha chains with dominant HER2/neu peptide recognition is not known, they may represent interesting tools for TCR optimization resulting in enhanced functionality when paired to novel partner chains. (PMID:20042572)
• Generation of T cell receptor response and signaling accelerates central nervous system autoimmune disease. (PMID:20145049)
• pTalpha expression patterns were markedly different in T-cell lymphoblastic leukemia cell lines. (PMID:20208138)
• T-cell receptor gene rearrangement is associated with Hodgkin lymphoma. (PMID:20496992)
• serine-dependent, HRD1-mediated ubiquitination targets TCRalpha to the ERAD pathway (PMID:20519503)
• Statistical analysis indicated that six genes, NFATC2, SCP2, CACNA1C, TCRA, POLE, and FAM3D, were associated with narcolepsy. (PMID:20677014)
• Cooperativity of point mutations of TCR (alpha and beta)that binds in vivo to HLA-A2 MHC and a viral peptide and found that the association rates were primarily responsible for the cooperativity. (PMID:20681514)
• Abnormal complementarity determining region CDR3a length distribution observed in transgenic regulatory T thymocytes is the result of intrinsically poor recognition of histocompatibility class II-peptide complexes by the transgenic TCR beta. (PMID:20713881)
• The adaptor LAT contains several conserved serine-based motifs, which are essential for proper signal transduction through the TCR. (PMID:20940326)
• the T cell receptor alphabeta (TCR-alphabeta) was significantly induced subsequent to stimulation with head and neck squamous cell carcinoma in-vitro (p = 0.009) and also present in metastatic lymph nodes in-vivo (PMID:21264308)
• Low peptide-histocompatibility complex (MHC) stability permits survival of T cells expressing self-reactive low peptide-MHC stability can permit the survival of T cells expressing self-reactive T cell receptors that bind in a traditional mode. (PMID:21282516)
• The cell polarity protein PALS1 is expressed in T lymphocytes and participates to the optimal activation of NF-kappaB following TCR stimulation. (PMID:21479189)
• study demonstrates that exogenous TCR alpha and beta chains transferred into the human immature RAG(+) T cell line Sup-T1 by lentiviral transduction inhibit RAG expression through tonic signaling (PMID:21481940)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

M1-specific T cell receptor alpha chain — P0DSE1 (reviewed: P0DSE1, P0DTU3)

Alternative names: TR alpha chain TRAV2701J4201C*01

All UniProt accessions (0):

UniProt curated annotations — full annotation on UniProt →

Function. The alpha chain of TRAV2701J4201C01/TRBV1901J2S701C02 alpha-beta T cell receptor (TR) clonotype that is specific for HLA-A02:01-restricted M/matrix protein 1 immunodominant epitope GILGFVFTL of influenza A virus (IAV). Classified as a public TR clonotype, it is preferentially selected in effector memory CD8-positive T cells among multiple HLA-A02:01 carriers and confers long-lived immunity against IAV infection. Can cross-recognize sporadically emerging IAV variants by molecular mimicry, inducing immunity toward different influenza strains. Antigen recognition initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn, ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell differentiation into effector/memory T cells.

Subunit / interactions. Disulfide-linked heterodimer with TRBV1901J2S701C02 beta chain. The TR primarily interacts via its CDR3-beta domain with M/matrix protein 1-derived peptide (GILGFVFTL) displayed by HLA-A02.01 in a ‘peg-notch’ recognition mode. The alpha-beta TR associates with the transmembrane signaling CD3 coreceptor proteins to form the TR-CD3 (TCR). The assembly of alpha-beta TR heterodimers with CD3 occurs in the endoplasmic reticulum where a single alpha-beta TR heterodimer associates with one CD3D-CD3E heterodimer, one CD3G-CD3E heterodimer and one CD247 homodimer forming a stable octameric structure. CD3D-CD3E and CD3G-CD3E heterodimers preferentially associate with TR alpha and TR beta chains (via TM domain), respectively. The association of the CD247 homodimer is the last step of TCR assembly in the endoplasmic reticulum and is required for transport to the cell surface.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in M/matrix protein 1-specific effector and memory CD8-positive T cells readily detectable in the peripheral blood, secondary lymphoid organs and lung (primary site of infection) of IAV infected individuals.

Domain organisation. The complementarity-determining region CDR1 confers specificity to the peptide antigen. Assumes a loop structure that makes contact with HLA-A02.01 and contributes to the stability of the TR through interaction with CDR3-beta loop. The complementarity-determining region CDR2 confers specificity to the peptide antigen. Assumes a loop structure that recognizes the peptide-HLA-A02-B2M complex. The complementarity-determining region CDR3 confers specificity to the peptide antigen. Assumes a loop structure that recognizes the peptide-HLA-A*02-B2M complex. The connecting peptide (CP) domain contributes to the TR-CD3 assembly and signal transduction. The TM domain mediates the interaction with the CD3 subunits.

Miscellaneous. The JM22 clone described as a variant of the public clonotype differs by one amino acid in the CDR3-alpha domain.

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR015370	TCR_alpha_C	Domain
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR052051	TCR_complex_component	Family

Pfam: PF07686, PF09291

UniProt features (48 total): region of interest 14, glycosylation site 11, disulfide bond 6, domain 4, mutagenesis site 3, signal peptide 2, chain 2, transmembrane region 2, topological domain 2, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
1OGA	X-RAY DIFFRACTION	1.4
8RLT	X-RAY DIFFRACTION	2.25
2VLR	X-RAY DIFFRACTION	2.3
8RLU	X-RAY DIFFRACTION	2.35
2VLJ	X-RAY DIFFRACTION	2.4
2VLK	X-RAY DIFFRACTION	2.5
5HHM	X-RAY DIFFRACTION	2.5
7NDQ	X-RAY DIFFRACTION	2.55
8RLV	X-RAY DIFFRACTION	2.61
9HI7	X-RAY DIFFRACTION	2.81
7NDU	X-RAY DIFFRACTION	2.9
5HHO	X-RAY DIFFRACTION	2.95
9NRJ	ELECTRON MICROSCOPY	3.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0DSE1-F1	88.77	0.63
AF-P0DTU3-F1	90.97	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

P0DSE1 (canonical)

Disulfide bonds (3): 41–107, 150–200, 222

Glycosylation sites (6): 36, 42, 160, 194, 205, 241

Mutagenesis-validated functional residues (3):

Position	Phenotype
48	decreases the affinity for m/matrix protein 1 peptide antigen.
49	decreases the affinity for m/matrix protein 1 peptide antigen.
51	decreases the affinity for m/matrix protein 1 peptide antigen.

P0DTU3

Disulfide bonds (3): 43–112, 157–207, 229

Glycosylation sites (5): 78, 167, 201, 212, 248

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (5): adaptive immune response (GO:0002250), T cell activation involved in immune response (GO:0002286), detection of tumor cell (GO:0002355), T cell mediated cytotoxicity directed against tumor cell target (GO:0002419), response to bacterium (GO:0009617)

GO Molecular Function (1): signaling receptor activity (GO:0038023)

GO Cellular Component (3): cell surface (GO:0009986), T cell receptor complex (GO:0042101), alpha-beta T cell receptor complex (GO:0042105)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	2
lymphocyte activation involved in immune response	1
T cell activation	1
response to tumor cell	1
detection of biotic stimulus	1
T cell mediated cytotoxicity	1
T cell mediated immune response to tumor cell	1
response to other organism	1
molecular transducer activity	1
cellular anatomical structure	1
plasma membrane signaling receptor complex	1
T cell receptor complex	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A075B6J2, A0A075B6J6, A0A075B6K6, A0A075B6L2, A0A075B6N2, A0A075B6R0, A0A0A0MS00, A0A0A0MS01, A0A0A0MS02, A0A0A6YYJ7, A0A0A6YYK1, A0A0A6YYK6, A0A0B4J1U4, A0A0B4J237, A0A0B4J244, A0A0B4J248, A0A0B4J262, A0A0C4DH27, A0A0C4DH28, A0JD36, P01627, P01633, P01634, P01637, P01639, P01641, P01642, P01697, P01718, P01723, P01731, P01735, P01737, P01738, P01740, P03978, P03979, P04210, P04214, P06315

Diamond homologs: A0A075B6L6, A0A075B6N1, A0A075B6N3, A0A075B6N4, A0A087WT01, A0A087WV62, A0A087X0K7, A0A087X0M5, A0A0A0MS03, A0A0A0MS04, A0A0A0MS05, A0A0A6YYD4, A0A0A6YYG2, A0A0A6YYG3, A0A0A6YYK4, A0A0B4J1U6, A0A0B4J263, A0A0B4J275, A0A0B4J2E0, A0A0C4DH59, A0A0C4DH69, A0A0J9YX75, A0A0J9YXY3, A0A0K0K1A3, A0A0K0K1A5, A0A0K0K1B3, A0A0K0K1C0, A0A0K0K1C4, A0A0K0K1D8, A0A0K0K1E9, A0A0K0K1G6, A0A0K0K1G8, A0A1B0GX31, A0A1B0GX49, A0A1B0GX51, A0A1B0GX78, A0A1B0GX95, A0A1B0GXF2, A0A539, A0A576

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

7 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	4
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

Disease associations

OMIM: gene `` | disease phenotypes: MIM:148300

GenCC curated gene-disease

Mondo (1): keratoconus (MONDO:0015486)

Orphanet (2): OBSOLETE: Keratoconus (Orphanet:156071), NON RARE IN EUROPE: Isolated keratoconus (Orphanet:2335)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000563	Keratoconus

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST000771_1	Narcolepsy	5.000000e-07
GCST001998_4	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)	4.000000e-06
GCST002260_2	Narcolepsy	5.000000e-49
GCST002912_4	Narcolepsy with cataplexy	1.000000e-11
GCST003484_2	Periodontal disease-related phenotype (Socransky)	2.000000e-09
GCST005522_1	Narcolepsy	9.000000e-30

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007780	periodontal measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007640	Keratoconus	C11.204.627

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzene	increases expression	2
Ethinyl Estradiol	affects expression, decreases expression	2
propionaldehyde	decreases expression	1
CGP 52608	increases reaction, affects binding	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	increases methylation	1
Copper Sulfate	increases expression	1
Simvastatin	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1424	MOLT-16	Cancer cell line	Female
CVCL_WN97	JE6-1REP-iNKT	Cancer cell line	Male

Clinical trials (associated diseases)

279 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01485211	PHASE4	COMPLETED	Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
NCT02119039	PHASE4	COMPLETED	Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
NCT03245853	PHASE4	COMPLETED	Epi-On Corneal Crosslinking for Keratoconus
NCT03429569	PHASE4	UNKNOWN	Cross-Linking ACcéléré Iontophorèse Confocal kératocONE
NCT04427956	PHASE4	COMPLETED	Corneal Crosslinking Treatment Study
NCT07474870	PHASE4	NOT_YET_RECRUITING	Outcomes of CTAK Surgery
NCT00371202	PHASE3	UNKNOWN	Comparison of Penetrating Keratoplasty and Deep Lamellar Keratoplasty With the Big Bubble Technique for Keratoconus
NCT00647699	PHASE3	COMPLETED	Corneal Collagen Cross-linking for Progressive Keratoconus
NCT00815256	PHASE3	UNKNOWN	Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus
NCT00887900	PHASE3	COMPLETED	Deep Anterior Lamellar Keratoplasty (DALK)
NCT01112072	PHASE3	UNKNOWN	Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia
NCT01152541	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
NCT01190306	PHASE3	TERMINATED	Safety Study of the VEGA UV-A System to Treat Keratoconus
NCT01344187	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01459679	PHASE3	TERMINATED	Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery
NCT01464268	PHASE3	UNKNOWN	Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia
NCT01604135	PHASE3	ACTIVE_NOT_RECRUITING	Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial
NCT01643226	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01672814	PHASE3	COMPLETED	Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus
NCT01682993	PHASE3	TERMINATED	Corneal Cross Linking and Topography Guided Excimer Laser Treatment
NCT01972854	PHASE3	TERMINATED	Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT02613780	PHASE3	UNKNOWN	Refractive Treatment of Early Keratoconus
NCT02638376	PHASE3	UNKNOWN	Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus
NCT03080077	PHASE3	UNKNOWN	Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia
NCT03187912	PHASE3	COMPLETED	Accelerated Corneal Cross-linking With Different Riboflavin Solutions
NCT03442751	PHASE3	COMPLETED	Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
NCT03858036	PHASE3	UNKNOWN	Corneal Collagen Cross-Linking (CXL) Performed With Epi-ON Versus Epi-OFF in Eyes With Keratoconus and Other Corneal Ectatic Disorders
NCT04897503	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose
NCT04905108	PHASE3	UNKNOWN	Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
NCT05027295	PHASE3	UNKNOWN	Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light
NCT06100939	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
NCT06100952	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
NCT06450470	PHASE3	RECRUITING	Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
NCT06601101	PHASE3	RECRUITING	Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus
NCT07124910	PHASE3	RECRUITING	Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
NCT07135167	PHASE3	RECRUITING	Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
NCT00409955	PHASE2	COMPLETED	Lamellar Transplant With Lyophilized Corneas
NCT00925327	PHASE2	UNKNOWN	Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus
NCT01143389	PHASE2	COMPLETED	Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
NCT01181219	PHASE2	COMPLETED	Transepithelial Corneal Collagen Cross-linking (CXL) in Treatment of Keratoconus